Close Menu

NEW YORK – The US Food and Drug Administration has approved Clovis Oncology's rucaparib (Rubraca) for men with BRCA1/2-mutated, metastatic castration-resistant prostate cancer who have previously received androgen receptor-directed therapy and taxane-based chemotherapy.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.